Table 1.
Study characteristics
| Number of knees | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Study | Type of study | Articulating spacer group(A) | Static spacer group(S) | Age (A/S years) | M/F | Follow-up (months) | Type of antibiotic | Type of articulating positioner | Literature quality (NOS) |
| Brunnekreef J 2013 | Retrospective | 26 | 9 | 61/58 | 15/20 | 12 | Gentamycin/erythromycin | Metal -polyethylene | 8 |
| Johnson AJ 2012 | Retrospective | 34 | 81 | 62/61 | NA | 27/66 | Vancomycin/tobramycin | Three different types | 7 |
| Choi HR 2012 | Retrospective | 14 (10) | 33 (31) | 64 | 23/24 | 58 | Vancomycin/ tobramycin | Original implant-bone cement | 7 |
| Chiang ER 2011 | Prospective | 23 (22) | 22 (21) | 71/72 | 22/23 | 41/40 | Vancomycin | Bone cement-bone cement | 7 |
| Park SJ 2010 | Retrospective | 16 | 20 | 66.5/60.2 | 4/32 | 36/29 | Vancomycin/erythromycin | Bone cement-bone cement | 8 |
| Freeman MG 2007 | Retrospective | 48 | 28 | 64.9/71.2 | NA | Total 71.2 62.2/86.6 | Vancomycin/tobramycin | Bone cement-bone cement | 6 |
| Hsu YC 2007 | Retrospective | 21 | 7 | – | NA | 58/101 | Vancomycin/tobramycin or gentamicin | Bone cement-bone cement | 8 |
| Jämsen E 2006 | Retrospective | 24 (22) | 10 (8) | 68/70 | 11/23 | 32 | NA | Original implant-bone cement | 8 |
| Emerson RH 2002 | Retrospective | 22 | 26 | 65.1/65.7 | 17/31 | 45.6/90 | Vancomycin/tobramycin | Bone cement-bone cement | 8 |
| Fehring TK 2000 | Retrospective | 30 (15)a | 25 | NA | NA | 27/36 | Tobramycin | Bone cement-bone cement | 7 |
Note: (1) The number in brackets in the sample size is the actual number of patients who completed the second revision and implantation of the new prosthesis (excluding the last document); (2) “NA” indicates that no information is available in the literature
aFifteen is the number of patients who have actually completed follow-up